Epidemiology and Infection

  • Epidemiology and Infection / Volume 141 / Issue 08 / August 2013, pp 1697-1704
  • Copyright © Cambridge University Press 2012 The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. The written permission of Cambridge University Press must be obtained for commercial re-use..
  • DOI: http://dx.doi.org/10.1017/S0950268812002257 (About DOI), Published online: 19 October 2012
  • OPEN ACCESS

Original Papers

Pneumococci, Klebsiella, Pseudomonas, and Staphylococci

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia

M. A. ELEMRAIDa1a2 c1, S. P. RUSHTONa3, M. D. F. SHIRLEYa3, M. F. THOMASa3a4, D. A. SPENCERa4, K. M. EASTHAMa5, F. HAMPTONa6, R. GORTONa7, K. POLLARDa1, A. R. GENNERYa1a2 and J. E. CLARKa1a2 on behalf of the North East of England Paediatric Respiratory Infection Study Group

a1 Department of Paediatric Infectious Disease and Immunology, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK

a2 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

a3 School of Biology, Newcastle University, Newcastle upon Tyne, UK

a4 Department of Respiratory Paediatrics, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK

a5 Department of Paediatrics, Sunderland Royal Hospital, Sunderland, UK

a6 Department of Paediatrics, James Cook University Hospital, Middlesbrough, UK

a7 Regional Epidemiology Unit, Health Protection Agency North East, Newcastle upon Tyne, UK

SUMMARY

In September 2006, the 7-valent pneumococcal conjugate vaccine (PCV7) was added to the UK immunization programme. We aimed to evaluate the impact of PCV7 on the incidence of all-cause community-acquired pneumonia (CAP) in children. A prospective survey was undertaken in 2008–2009 at 11 hospitals in North East England of children aged 0–16 years with radiologically confirmed pneumonia. Data were compared to those from a similar survey undertaken in the same hospitals in 2001–2002. A total of 542 children were enrolled, of which 74% were aged <5 years. PCV7 uptake was 90·7%. The incidence of pneumonia was 11·8/10 000 [95% confidence interval (CI) 10·9–12·9], and the hospitalization rate was 9·9/10 000 (95% CI 9·0–10·9). Compared to 2001, there was a 19% (95% CI 8–29) reduction in the rate of CAP in those aged <5 years, and in those <2 years a 33·1% (95% CI 20–45) reduction in the incidence of CAP and 38·1% (95% CI 24–50) reduction in hospitalization rates. However, for those unvaccinated aged ≥5 years, there was no difference in the incidence of CAP and hospitalization rate between both surveys. Since 2001, the overall reduction in incidence was 17·7% (95% CI 8–26) and for hospitalization 18·5% (95% CI 8–28). For the <5 years age group there was a lower incidence of CAP in PCV7-vaccinated children (25·2/10 000, 95% CI 22·6–28·2) than in those that were not vaccinated (37·4/10 000, 95% CI 29·2–47·1). In conclusion, PCV7 has reduced both incidence and rate of hospitalization of pneumonia in children, particularly in the <2 years age group.

(Received June 20 2012)

(Revised September 09 2012)

(Accepted September 10 2012)

(Online publication October 19 2012)

Key words

  • Children;
  • incidence;
  • pneumococcal conjugate vaccine;
  • pneumonia

Correspondence

c1 Author for correspondence: Dr M. A. Elemraid, Great North Children's Hospital, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK. (Email: mohamed.elemraid@ncl.ac.uk)

Metrics